SEC Form 4 FORM 4	UNITED STAT	ES SECURITIES AND EXCHANGE CO	MMISSION							
		Washington, D.C. 20549		OMB APPROVAL						
to Section 16. Form 4 or Form 5 obligations may continue. See		IT OF CHANGES IN BENEFICIAL OWN pursuant to Section 16(a) of the Securities Exchange Act of 1934	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5							
. ,		or Section 30(h) of the Investment Company Act of 1940								
1. Name and Address of Reporting Pe <u>Raykov Rosty</u>	rson*	2. Issuer Name and Ticker or Trading Symbol <u>FENNEC PHARMACEUTICALS INC.</u> [ FENC ]	5. Relationship of F (Check all applicab Director	10% Owner						
(Last) (First) C/O FENNEC PHARMACEUT	(Middle) TCALS, INC.	3. Date of Earliest Transaction (Month/Day/Year) 07/31/2024	below)	below) XECUTIVE OFFICER						
PO BOX 13628, 68 TW ALEX.	ANDER DRIVE	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joir Line)	nt/Group Filing (Check Applicable						
(Street) RESEARCH TRIANGLE NC	27709			by One Reporting Person by More than One Reporting						
PARK	27709	Rule 10b5-1(c) Transaction Indication								
(City) (State)	(Zip)	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.					5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	<ul> <li>Reported Transaction(s) (Instr. 3 and 4)</li> </ul>		(Instr. 4)	
Common shares <sup>(1)</sup>	07/31/2024		A		2,431	A	\$ <mark>0</mark>	189,902	D		
Common shares <sup>(2)</sup>	08/01/2024		S		2,431	D	\$6.255	187,471	D		

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of		6. Date Exerc Expiration Da (Month/Day/Y	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Represents release of restriction from shares awarded 3-31-2023

2. Represents shares sold pursuant to a 10b5-1 plan dated December 14, 2023.

## <u>/s/ Rostislav Raykov</u>

\*\* Signature of Reporting Person Date

08/01/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.